Sarepta Therapeutics (SRPT) Expected to Announce Earnings on Wednesday

Sarepta Therapeutics (NASDAQ:SRPT) is anticipated to issue its quarterly earnings data after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $1.38 per share and revenue of $631.03 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $105.35 on Wednesday. The company has a market capitalization of $10.06 billion, a price-to-earnings ratio of 84.28 and a beta of 0.75. Sarepta Therapeutics has a 12 month low of $101.15 and a 12 month high of $173.25. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a 50 day moving average of $118.57 and a 200 day moving average of $124.07.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Monday, January 27th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. HC Wainwright restated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 13th. Finally, StockNews.com lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $176.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.